Member Info for davidpqz

It says in the RNS, "No trading in the stock - voting control interest over stock transferred to new manager". However if you need something to worry about try this one. W's holding in RENE in aggregate was just below the level at which he would have had to make a compulsory takeover bid for the company. It is quite likely that a big pharma co. will try to acquire them. One way to prevent them from taking over the company is to issue more shares. And we know that RENE will require further capital for the next trials and from past experience RENE goes for broke when they raise capital. Dilution could be on the cards.

There are no open short positions showing on the FCA's website.

Three months until they start the Woodford wind up. They state that sales will be gradual (they're not fools). A lot can happen in three months.

and definitely not today !

Reneto40. The actor who played Marvin the Paranoid Android died recently. There might be an opening for you. :-)They have a cure for blindness and for paralysis. This share will multibag one day, it just might not be tomorrow.

Clinical trials are of necessity painstaking (remember thalidomide?). Michael Hunt is quietly spoken so it might pay to listen carefully to what he says, such as the following :
''What we're seeing is hugely encouraging and I think the principal investigator will make that clear when he presents the data next weekend''.

Many thanks for the intelligent and (mercifully) respectful discussion here. I just have one point to make. The phrase used is that a three line improvement is clinically meaningful. As testing proceeds with patients with a higher baseline visual acuity surely this figure must reduce otherwise (to take an extreme example) you could end up with the requirement that the improvement needs to be better than 20:20 to be meaningful. I'm not a statistician but I suspect that JD's analysis is linear whereas the analysis should somehow be asymptotic to the 20:20 line? 37 letters is 7 lines - I think you're soon going to run out of chart!

Thought you might need some light relief.

Maybe there were wider forces at work as well today. Seems like markets globally have had a bout of the jitters
https://www.bbc.co.uk/news/business-49912390
If your eyesight was deteriorating due to RP and you were offered a treatment which could halt it and even improve your vision by 2 to 3 lines on the eyesight chart what would you say?
Maybe that's a bit simplistic.
The surgical procedure related loss of vision is serious even though it's not related to the treatment and really needs to be explained. My worry is that it might have a bearing on the ethics of continuing the trials. Maybe this has helped to spook the market.
Overall this is working very well indeed although there may be a few further problems to resolve.

I calculate that the final 3 patients at 6 months had an average visual acuity improvement of 12.6 letters.

£12 might not be as crazy as it sounds - just look at the sp in Jan 2007 !

https://www.youtube.com/watch?v=w-OiUg7dmGI

Don't encourage it. Up to now the discussion has been informative.

If high street shops are closing at such an alarming rate, where are all the shoppers going? Just asking.

It's anecdotal I know, but it took a week after some good news for RENE in the spring for the sp to catch fire. It just takes a little time for people to catch on.

I very much agree. The oost was at 00.10 in case anyone missed it :-)

From RNS 8.05.19 "The Company expects the PISCES III clinical trial, if positive, to be one of two pivotal studies required to support marketing authorisations for CTX in stroke disability."
Why another one and how long to market?

RNS 24.01.19 " Top-line results from the study are expected in early 2020. "
It's now a year later H1 2021
On the plus side, when positive results were announced from the phase 1 trial in April 2015 the share price rose from 350 to 615p (adjusted for 100 to 1 consolidation for comparison). As someone said, maybe Woodford is just presenting us with a buying opportunity!

Slow take up is perhaps understandable. In the original study 30% of patients experienced a significant positive effect. With a placebo this reduces to 15%. Maybe it's too big an ask and might why they talk of changing the protocol.

It's not the House of Commons you need to watch - it's the other blond buffoon on the other side of the pond !